The proportion of families with at least one initially healthy household contact in whom influenza developed was smaller in the zanamivir group than in the placebo group (4 percent vs. 19 percent ...

Cite this: Zanamivir for the Treatment of Clinically Diagnosed Influenza in Clinical Practice: Results of the Valuable-Insights-From-Patients Study - Medscape - Nov 01, 2000.

Correspondence Zanamivir to Prevent Influenza Published February 15, 2001 N Engl J Med 2001;344: 528 - 530 DOI: 10.1056/NEJM200102153440714 ...

Zanamivir is a novel neuraminidase inhibitor with potent and specific antiviral activity against all influenza A and B neuraminidase subtypes at concentrations that can readily be attained in the ...

The large study enrolled 865,032 outpatients treated with inhaled zanamivir (n = 595,897) or oral oseltamivir (269,135) within 48 hours of being diagnosed with influenza.

Zanamivir prophylaxis correlated with a reduction in symptomatic influenza in individuals (risk difference, 1.98 percent).

Naoki Kawai, Hideyuki Ikematsu, Nobuo Hirotsu, Tetsunari Maeda, Takashi Kawashima, Osame Tanaka, Satoshi Yamauchi, Kenichi Kawamura, Shinro Matsuura, Mika Nishimura, Norio Iwaki, Seizaburo Kashiwagi, ...

Review of NICE Technology Appraisal Guidance No.158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza, and No.168; Amantadine, oseltamivir and zanamivir for the treatment of ...